RESET-SLE is a study for adults with Systemic Lupus Erythematosus (SLE), a long-term disease where the immune system attacks the body. It can cause lasting damage to different body parts, especially the kidneys, called Lupus Nephritis (LN). This study checks if a new cell therapy, CABA-201, is safe and works well. Patients with active SLE (either with or without kidney issues) can try this treatment. They will receive one dose of CABA-201 after getting other medicines called Cyclophosphamide (CY) and Fludarabine (FLU) to prepare their bodies.

• Participants need to be between 18 and 65 years old.
• They must have an SLE diagnosis with specific antibodies, and for LN patients, a proven kidney condition.
• This study involves checking for any severe health issues that could make it unsafe for you.

If you've had a severe reaction to similar medicines, have an active infection, or received certain transplants, you cannot join. It's important to talk with your doctor to see if this study is right for you.